Exanthem disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: EXN002 MIFTS: 61	Exanthem Categories: Skin diseases, Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Exanthem

MalaCards integrated aliases for Exanthem:

Name: Exanthem ¹² ¹⁵

Exanthema ¹² ⁴⁴

Rashes ⁴³

Rash ¹²

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Symptoms and signs involving the skin and subcutaneous tissue

Rash and other nonspecific skin eruption

External Ids:

Disease Ontology ¹² DOID:0050486

ICD10 ³³ R21

ICD9CM ³⁵ 782.1

MeSH ⁴⁴ D005076

NCIt ⁵⁰ C111884 C39594

SNOMED-CT ⁶⁸ 112625008 139684003 158230006 more

UMLS ⁷³ C0015230

Sources

Summaries for Exanthem

MedlinePlus : ⁴³ A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes. Contact dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to aseptic meningitis and mumps. An important gene associated with Exanthem is CD40LG (CD40 Ligand), and among its related pathways/superpathways are ERK Signaling and Innate Immune System. The drugs Cetuximab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : ⁷⁶ An exanthem or exanthema (from Greek ἐξάνθημα exánthēma, \"a breaking out\") is a widespread rash... more...

Sources

Related Diseases for Exanthem

Diseases in the Exanthem family:

Bacterial Exanthem

Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 349)

#	Related Disease	Score	Top Affiliating Genes
1	aseptic meningitis	30.8	IL1RN NLRP3 TNF
2	mumps	29.9	CD40LG IL2 TNF
3	chikungunya	29.9	CD40LG IL6 TNF
4	meningoencephalitis	29.7	CD40LG CD79A IL6 TLR9
5	cryopyrin-associated periodic syndrome	29.6	CRP IL1RN IL6 NLRP3
6	pneumonia	29.2	CD40LG CRP IL6 TLR9 TNF
7	meningitis	29.2	CD40LG CRP IL6 NLRP3 TLR9 TNF
8	prostatitis	29.2	IL2 IL6 TNF
9	graft-versus-host disease	28.9	IL2 IL6 TNF
10	arthritis	28.9	IL1RN IL6 TNF TNFRSF1B
11	acquired immunodeficiency syndrome	28.6	CD40LG CD79A IL2 IL6 TNF
12	brucellosis	28.1	CD40LG CRP IL1RN IL2 IL6 TNF
13	myeloma, multiple	26.2	CD40LG CD79A CRP HRAS IL2 IL6
14	exanthema subitum	12.3
15	viral exanthem	12.1
16	bacterial exanthem	11.9
17	hand, foot and mouth disease	11.3
18	selective igg deficiency disease	11.1	CD40LG CD79A
19	c1q nephropathy	11.1	CD40LG CD79A
20	meningovascular neurosyphilis	11.0	CD40LG CD79A
21	alpha chain disease	11.0	CD40LG CD79A
22	brill-zinsser disease	11.0	CD40LG CD79A
23	exudative glomerulonephritis	11.0	CD40LG CD79A
24	cork-handlers' disease	11.0	CD40LG CD79A
25	salpingo-oophoritis	11.0	CD40LG CD79A
26	breast intraductal proliferative lesion	11.0	EGFR ERBB2
27	early yaws	11.0	CD40LG CD79A
28	ventilation pneumonitis	11.0	CD40LG CD79A
29	chronic interstitial cystitis	11.0	CD40LG CD79A
30	axillary adenitis	11.0	CD40LG CD79A
31	cryofibrinogenemia	11.0	CD40LG CD79A
32	contagious pustular dermatitis	11.0
33	severe cutaneous adverse reaction	11.0
34	sigmoid neoplasm	10.9	HRAS KRAS
35	schnitzler syndrome	10.9	CD40LG IL1RN NLRP3
36	transient neonatal thrombocytopenia	10.9	CD79A TRIM21
37	ocular toxoplasmosis	10.9	CD40LG CD79A TLR9
38	trichostrongyloidiasis	10.9	CD40LG CD79A
39	conjunctival disease	10.9	CD40LG CD79A NLRP3
40	subacute bacterial endocarditis	10.8	CD40LG CD79A
41	heterophyiasis	10.8	CD40LG CD79A
42	autoimmune disease of urogenital tract	10.8	CD40LG CD79A TLR9
43	immunoglobulin g deficiency	10.8	CD40LG CD79A
44	acute maxillary sinusitis	10.8	CD40LG CD79A CRP
45	hypersensitivity vasculitis	10.8	CD40LG CD79A CRP
46	pyelitis	10.8	CD40LG CD79A CRP
47	mature b-cell neoplasm	10.8	CD40LG CD79A TLR9
48	lung adenoid cystic carcinoma	10.8	EGFR HRAS KRAS
49	b cell deficiency	10.8	CD40LG CD79A TLR9
50	endocardium disease	10.8	CD40LG CD79A CRP

Graphical network of the top 20 diseases related to Exanthem:

Sources

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

²⁶ (show all 18)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	10.32	MTOR HRAS KALRN EGFR KRAS
2	Decreased viability	GR00106-A-0	10.32	KRAS
3	Decreased viability	GR00221-A-1	10.32	KRAS HRAS MTOR EGFR
4	Decreased viability	GR00221-A-2	10.32	KRAS HRAS
5	Decreased viability	GR00221-A-3	10.32	HRAS
6	Decreased viability	GR00221-A-4	10.32	MTOR EGFR
7	Decreased viability	GR00301-A	10.32	KALRN KRAS
8	Decreased viability	GR00342-S-1	10.32	MTOR KALRN
9	Decreased viability	GR00342-S-2	10.32	MTOR KALRN
10	Decreased viability	GR00342-S-3	10.32	KALRN
11	Decreased viability	GR00381-A-1	10.32	KALRN KRAS
12	Decreased viability	GR00402-S-2	10.32	HRAS MTOR KALRN EGFR KRAS
13	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	9.73	ERBB2 HRAS MTOR HSPG2 KALRN EGFR
14	Decreased cell migration	GR00055-A-1	9.72	MTOR EGFR KRAS HRAS KALRN
15	Decreased viability with paclitaxel	GR00179-A-1	9.7	EGFR ERBB2 MTOR
16	Decreased viability with paclitaxel	GR00179-A-2	9.7	MTOR
17	Decreased viability with paclitaxel	GR00179-A-3	9.7	EGFR MTOR
18	Reduced mammosphere formation	GR00396-S	9.23	TLR9 TNFRSF1B KRAS HRAS MTOR HSPG2

MGI Mouse Phenotypes related to Exanthem:

⁴⁶ (show all 21)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.51	HRAS IL1RN IL2 ERBB2 HSPG2 KALRN
2	cardiovascular system	MP:0005385	10.47	IL6 KRAS HRAS IL1RN IL2 ERBB2
3	cellular	MP:0005384	10.44	IL6 KRAS IL1RN IL2 ERBB2 HSPG2
4	immune system	MP:0005387	10.43	IL6 KRAS IL1RN IL2 HSPG2 TNFRSF1B
5	hematopoietic system	MP:0005397	10.42	IL6 KRAS IL1RN IL2 HSPG2 TNFRSF1B
6	mortality/aging	MP:0010768	10.41	IL6 HRAS KRAS IL1RN IL2 ERBB2
7	growth/size/body region	MP:0005378	10.4	IL1RN HRAS IL6 IL2 KALRN ERBB2
8	integument	MP:0010771	10.36	IL6 KRAS HRAS IL1RN ERBB2 HSPG2
9	digestive/alimentary	MP:0005381	10.35	IL6 KRAS HRAS IL2 ERBB2 HSPG2
10	endocrine/exocrine gland	MP:0005379	10.35	IL6 HRAS KRAS IL2 ERBB2 KALRN
11	nervous system	MP:0003631	10.22	HRAS IL6 KALRN HSPG2 ERBB2 TNFRSF1B
12	liver/biliary system	MP:0005370	10.15	IL6 IL2 HSPG2 TNFRSF1B EGFR TNF
13	craniofacial	MP:0005382	10.13	ERBB2 HSPG2 HRAS TNFRSF1B EGFR TNF
14	muscle	MP:0005369	10.11	IL6 KALRN ERBB2 HSPG2 TNFRSF1B EGFR
15	neoplasm	MP:0002006	10.09	HRAS IL6 KRAS IL2 ERBB2 TNFRSF1B
16	renal/urinary system	MP:0005367	10.06	IL6 HRAS KRAS TNFRSF1B EGFR CD40LG
17	reproductive system	MP:0005389	10	IL1RN IL6 IL2 KALRN ERBB2 AREG
18	no phenotypic analysis	MP:0003012	9.97	HRAS IL2 KALRN EGFR CD79A TNF
19	respiratory system	MP:0005388	9.85	HRAS IL6 KRAS IL2 ERBB2 HSPG2
20	skeleton	MP:0005390	9.73	IL6 HRAS KRAS IL1RN ERBB2 HSPG2
21	vision/eye	MP:0005391	9.23	HSPG2 IL6 IL2 AREG TNFRSF1B EGFR

Sources

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1176)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cetuximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

205923-56-4

56842117 2333

Fluorouracil

Approved

Phase 4,Phase 3,Phase 2,Phase 1

51-21-8

3385

Irinotecan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

97682-44-5, 100286-90-6

60838

Menthol

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

2216-51-5

16666

Zinc

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

7440-66-6

23994

Zinc oxide

Approved

Phase 4,Phase 3,Not Applicable

1314-13-2

Vancomycin

Approved

Phase 4,Phase 3,Not Applicable

1404-90-6

441141 14969

Gabapentin

Approved, Investigational

Phase 4,Phase 2

60142-96-3

3446

gamma-Aminobutyric acid

Approved, Investigational

Phase 4,Phase 2

56-12-2

119

Piperacillin

Approved

Phase 4,Not Applicable

66258-76-2

43672

Sulbactam

Approved

Phase 4,Phase 2

68373-14-8

Azithromycin

Approved

Phase 4,Phase 3,Phase 2,Early Phase 1

83905-01-5

55185 447043

Piperaquine

Approved, Investigational

Phase 4,Phase 2,Phase 3,Not Applicable

4085-31-8

5079497

Pyrimethamine

Approved, Investigational, Vet_approved

Phase 4,Phase 1,Phase 2

58-14-0

4993

Sulfadoxine

Approved, Investigational

Phase 4,Phase 1,Phase 2

2447-57-6

17134

Ketorolac

Approved

Phase 4,Not Applicable

74103-06-3, 66635-83-4

3826

Latanoprost

Approved, Investigational

Phase 4

130209-82-4

5282380 5311221

Travoprost

Approved

Phase 4

157283-68-6

5282226

Iron

Approved

Phase 4,Phase 2,Not Applicable

7439-89-6

23925

Cefazolin

Approved

Phase 4,Phase 3,Not Applicable

25953-19-9

656510 33255

Histamine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

75614-87-8, 51-45-6

774

Ketotifen

Approved

Phase 4,Phase 3

34580-14-8, 34580-13-7

3827

Adapalene

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

106685-40-9

60164

Benzoyl peroxide

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

94-36-0

7187

Clindamycin

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

18323-44-9

29029

4-Aminopyridine

Approved

Phase 4

504-24-5

1727

Pinaverium

Approved

Phase 4

59995-65-2

Cefuroxime

Approved

Phase 4,Phase 2,Not Applicable

55268-75-2

5361202 5479529

Ciprofloxacin

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

85721-33-1

2764

Clarithromycin

Approved

Phase 4,Not Applicable

81103-11-9

84029

Moxifloxacin

Approved, Investigational

Phase 4,Phase 1

354812-41-2, 151096-09-2

152946

Penicillin G

Approved, Vet_approved

Phase 4

61-33-6

5904

Salmon Calcitonin

Approved, Investigational

Phase 4

47931-85-1

16129616

Tazobactam

Approved

Phase 4,Not Applicable

89786-04-9

123630

Nevirapine

Approved

Phase 4,Phase 3,Phase 1,Phase 2

129618-40-2

4463

Prednisone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

53-03-2

5865

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

22916-47-8

4189

sodium fluoride

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

7681-49-4

Lamivudine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

134678-17-4

60825

Tacrolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

104987-11-3

445643 439492

Sunitinib

Approved, Investigational

Phase 4,Phase 2,Phase 1

341031-54-7, 557795-19-4

5329102

Salicylic acid

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

69-72-7

338

Sorafenib

Approved, Investigational

Phase 4,Phase 2

284461-73-0

216239 406563

Clobetasol

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

25122-46-7, 25122-41-2

32798 5311051

Triamcinolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

124-94-7

31307

Rifampicin

Approved

Phase 4,Phase 1,Phase 2

13292-46-1

5458213 5381226

Etanercept

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

185243-69-0

Etomidate

Approved

Phase 4

33125-97-2

36339 667484

Propofol

Approved, Investigational, Vet_approved

Phase 4,Phase 2,Not Applicable

2078-54-8

4943

Efavirenz

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

154598-52-4

64139

Interventional clinical trials:

(show top 50) (show all 2951)

#	Name	Status	NCT ID	Phase	Drugs
1	Elmex Gel Efficacy in Preventing White Spot Lesions	Unknown status	NCT00268138	Phase 4	elmex gel
2	FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema	Unknown status	NCT01315990	Phase 4	FOLFIRI + Cetuximab
3	Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants	Unknown status	NCT02716415	Phase 4	Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
4	Line Versus Spot Ablation in Persistent Atrial Fibrillation	Unknown status	NCT00196157	Phase 4
5	Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients	Unknown status	NCT02605213	Phase 4	Vancomycin;Placebo
6	A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder	Unknown status	NCT00837343	Phase 4	quetiapine fumarate tablet (Seroquel)
7	Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission	Unknown status	NCT01901666	Phase 4	Growth Hormone
8	Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome	Unknown status	NCT02424695	Phase 4	Gabapentin Enacarbil (GEn);Placebo
9	Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults	Unknown status	NCT01811823	Phase 4
10	Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old	Unknown status	NCT02806531	Phase 4
11	Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection	Unknown status	NCT01897831	Phase 4	xin te mie
12	Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection	Unknown status	NCT01760109	Phase 4	Piperacillin Sodium and Sulbactam Sodium
13	A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women	Unknown status	NCT02575755	Phase 4	Azithromycin plus piperaquine phosphate;Sulfadoxine-pyrimethamine
14	The Laser in Pseudoexfoliation (LIP) Study	Unknown status	NCT01704989	Phase 4	Prostagladin
15	Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension	Unknown status	NCT02796560	Phase 4	Brand name travoprost;Generic travoprost
16	The Use of Iron Therapy for Patients With Anemia After Surgery	Unknown status	NCT01975272	Phase 4	Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
17	The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection	Unknown status	NCT02307006	Phase 4	Ceftaroline;Cefazolin / Vancomycin
18	Ketotifen as a Treatment for Vascular Leakage During Dengue Fever	Unknown status	NCT02673840	Phase 4	Ketotifen;Placebo
19	Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products	Unknown status	NCT02731105	Phase 4	Acnatac® Gel left face;Epiduo® Gel right face;Acnatac® Gel right face;Epiduo® Gel left face
20	Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris	Unknown status	NCT01448733	Phase 4	Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
21	A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne	Unknown status	NCT01422785	Phase 4	clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
22	Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)	Unknown status	NCT01260571	Phase 4	Benzoyl peroxide and sulfur
23	Resistance Training and Amino Pyridine in Multiple Sclerosis	Unknown status	NCT02143167	Phase 4	SR-fampridine;Placebo
24	Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)	Unknown status	NCT01553032	Phase 4	Erbitux®
25	Targeted Indoor Residual Spraying Against Malaria	Unknown status	NCT02556242	Phase 4
26	Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction	Unknown status	NCT02833103	Phase 4	Danshu Capsules;Pinaverium Bromide
27	Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections	Unknown status	NCT02171338	Phase 4
28	Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash	Completed	NCT00219466	Phase 4
29	Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT	Completed	NCT00647205	Phase 4
30	MI Varnish for the Prevention of White Spot Lesions	Completed	NCT03446690	Phase 4	MI Varnish
31	Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients	Completed	NCT01329731	Phase 4	elmex® gelée;negative control (placebo)
32	Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients	Completed	NCT02184299	Phase 4	Nevirapine;Prednisone
33	Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot	Completed	NCT02742285	Phase 4	Artemether + lumefantrine
34	Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study	Completed	NCT00723515	Phase 4	sodium fluoride;sodium fluoride calcium fluoride
35	MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study	Completed	NCT02424097	Phase 4	CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste;1,100pm F-toothpaste and 0.5%NaF rinse
36	Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients	Completed	NCT01768390	Phase 4
37	Genotype Based Personalized Prescription of Nevirapine	Completed	NCT00986063	Phase 4
38	Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots	Completed	NCT01149876	Phase 4	Tretinoin cream 0.05
39	Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants	Completed	NCT00702507	Phase 4	0.25 % Miconazole Nitrate Ointment
40	Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.	Completed	NCT01195194	Phase 4	PRE-TRANSPLANT (PRE=before)
41	Comparison of the Effect of Fluoride Remineralizer Gel and Foam	Completed	NCT02490592	Phase 4
42	Efficacy of Pentoxifylline on Chronic Kidney Disease	Completed	NCT00155246	Phase 4	pentoxifylline (drug)
43	Subcutaneous Amifostine Safety Study	Completed	NCT00158041	Phase 4	Amifostine administered subcutaneously
44	Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy	Completed	NCT01797861	Phase 4
45	Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China	Completed	NCT02898922	Phase 4
46	SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle	Completed	NCT01242852	Phase 4
47	Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients	Completed	NCT01402089	Phase 4	Sunitinib;Erlotinib;Midazolam;Caffeine
48	A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster	Completed	NCT02152800	Phase 4	valacyclovir hydrocholoride
49	Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra	Completed	NCT01389557	Phase 4	Dihydroartemisinin-piperaquine with primaquine
50	Bipolar Study in Adults at Least 18 Years of Age	Completed	NCT00067938	Phase 4	lamotrigine

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Sources

Genetic Tests for Exanthem

Sources

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

⁴¹

Skin, Eye, Testes, Breast, Kidney, Lung, Bone

Sources

Publications for Exanthem

Articles related to Exanthem:

(show top 50) (show all 267)

#	Title	Authors	Year
1	Ten-year-old traveller with fever and an exceptional exanthem. ( 29314384 )		2018
2	Acral-accentuated exanthem in an infant with parechovirus meningitis. ( 29205494 )	Lee D....Chong J.	2018
3	What's in a Rash? Viral Exanthem Versus CBRNE Exposure: Teleconsultation Support for Two Special Forces Soldiers With Diffuse Rash in an Austere Environment. ( 29889970 )	Lee H.D....Pamplin J.C.	2018
4	Asymmetric periflexural exanthem: not a distinctive disease of childhood. ( 29582621 )	Balestri R....Girardelli C.R.	2018
5	Ten-year-old traveller with fever and an exceptional exanthem. ( 29314380 )	Osowicki J....SauvAc L.	2018
6	50 Years Ago in The Journal of Pediatrics: Atypical Exanthem after Exposure to Natural Measles: Eleven Cases in Children Previously Inoculated with Killed Vaccine. ( 29389454 )	Toltzis P.	2018
7	Exanthem, Fieber und Arthralgien bei einer 19-jAohrigen Patientin. ( 29645383 )	HAPllweger N....Nguyen V.A.	2018
8	Unilateral laterothoracic exanthem. ( 28754336 )	Lozano-Masdemont B.	2017
9	Can Unilateral Pityriasis Rosea be Considered a Form of Superimposed Lateralized Exanthem? ( 28764276 )	Drago F....Parodi A.	2017
10	TherapierefraktAores Exanthem eines sechs Monate alten SAouglings. ( 29228485 )	Weingast J....Radakovic S.	2017
11	Superimposed lateralized exanthem in a 30-year-old woman. ( 28893877 )	AlcA!ntara-Reifs C.M....Salido-Vallejo R.	2017
12	Image Gallery: Flagellate bullous exanthem in chikungunya. ( 29052889 )	Vinay K....Dogra S.	2017
13	Epstein-Barr virus exanthem in an adult patient with myelodysplastic syndrome. ( 29274098 )	Drago F....Rebora A.	2017
14	Exanthem und Ekzem bei einem anderthalbjAohrigen Jungen. ( 28214315 )	Thielking F....FAPlster-Holst R.	2017
15	Dengue-Fieber und die Differenzialdiagnosen zu Exanthem, Fieber und Kopfschmerzen nach Fernreise. ( 28140551 )	Tjandra E.T....SunderkAPtter C.	2017
16	IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. ( 28856664 )	Lee N....Saavedra A.P.	2017
17	Assessment of histopathological features of maculopapular viral exanthem and drug-induced exanthem. ( 28914958 )	Singh S....Kabra S.K.	2017
18	Acute localized exanthem due to Coxsackievirus A4. ( 28956547 )	Drago F....Parodi A.	2017
19	Asymmetric periflexural/unilateral laterothoracic exanthem related to parvovirus B19 infection: An adult carrier of A9-globin thalassaemia gene mutation in Hong Kong. ( 29896828 )	Chuh A.	2016
20	Image Gallery: A case of unilateral laterothoracic exanthem. ( 27996140 )	Woo S.H....Park J.	2016
21	Exanthem subitum (human herpesvirus-6 reactivation) after autologous stem cell transplantation. ( 26918962 )	Schlaweck S....Mayer K.	2016
22	&quot;Tache noire&quot;: diagnostic clue in a febrile exanthem. ( 28038854 )	Velasco-Tamariz V....MaroA+as-JimAcnez L.	2016
23	Urticarial exanthem associated with Capnocytophaga canimorsus bacteremia after a dog bite. ( 27051842 )	Jordan C.S....Mengden S.J.	2016
24	Lateralized exanthem mimicking figurate inflammatory dermatosis of infancy after methimazole therapy. ( 27272160 )	Arrigo T....Altavilla D.	2016
25	Monitoring of human herpesviruses-6 and -7 DNA in saliva samples during the acute and convalescent phases of exanthem subitum. ( 27648817 )	Miyazaki Y....Yamada M.	2016
26	Eruptive hypomelanosis in a child, a new viral exanthem. ( 26728822 )	Zawar V....Chuh A.	2016
27	Anogenital allergic contact dermatitis caused by methylchloroisothiazolinone, methylisothiazolinone and topical clotrimazole with subsequent generalized exanthem triggered by oral fluconazole. ( 27040872 )	Nasir S....Goldsmith P.	2016
28	A mini-epidemic of eruptive hypomelanosis in three children of the same family; the first piece of epidemiological evidence for an infectious cause of a novel paraviral exanthem. ( 27038439 )	Chuh A....Bharatia P.	2016
29	Coxsackievirus A6 Polymorphic Exanthem in Israeli Children. ( 26463513 )	Renert-Yuval Y....Molho-Pessach V.	2016
30	Stammbetontes Exanthem mit Allgemeinsymptomatik. ( 26972204 )	Delavari D....Hartmann M.	2016
31	Pityriasis Rosea, Gianotti-Crosti Syndrome, Asymmetric Periflexural Exanthem, Papular-Purpuric Gloves and Socks Syndrome, Eruptive Pseudoangiomatosis, and Eruptive Hypomelanosis: Do Their Epidemiological Data Substantiate Infectious Etiologies? ( 27103975 )	Chuh A....Lee A.	2016
32	Unilateral Exanthem. ( 26120168 )	George A....Kanish B.	2015
33	Purpuric exanthem caused by Ross River virus infection. ( 25551310 )	Allanson B....Wood B.A.	2015
34	Unilateral Laterothoracic Exanthem. ( 26187001 )	Leung A.K....Barankin B.	2015
35	Localized exanthem due to echovirus 9. ( 25919440 )	Drago F....Parodi A.	2015
36	Febrile Exanthem with Hyperferritinemia. ( 26705442 )	Caputo G.M....Ryan E.F.	2015
37	Aminopenicillin-associated exanthem: lymphocyte transformation testing revisited. ( 25323308 )	Trautmann A....Kerstan A.	2014
38	Eruptive hypomelanosis: a novel exanthem associated with viral symptoms in children. ( 25229328 )	Zawar V....Chuh A.	2014
39	Superimposed lateralized exanthem of childhood: report of a case related to adenovirus infection. ( 24635078 )	Niedermeier A....Happle R.	2014
40	Vesiculobullous viral exanthem due to chikungunya in an infant. ( 25593800 )	Singh N....Dhodapkar R.	2014
41	Unilateral laterothoracic or asymmetric periflexural exanthem: is time to change the name of the disease? ( 25267301 )	Drago F....Rebora A.	2014
42	Black heel (talon noir) associated with a viral exanthem. ( 24222298 )	Sardana K....Sagar V.	2013
43	Acetaminophen-induced exanthem of the breasts. ( 22838093 )	Arora R....Maddox C.L.	2012
44	Unilateral laterothoracic exanthem. ( 21989468 )	Gragasin F.S....Metelitsa A.I.	2012
45	Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. ( 22290027 )	Gavini A....Olszewski A.J.	2012
46	Febrile illness with papular and vesicular exanthem and ulceronecrotic plaques. ( 23106676 )	Castelo-Soccio L.A....Shah K.N.	2012
47	Histopathology of measles exanthem: a case with characteristic features and eosinophils. ( 22725635 )	Sheikine Y....Zimarowski M.J.	2012
48	Gianotti-Crosti syndrome, pityriasis rosea, asymmetrical periflexural exanthem, unilateral mediothoracic exanthem, eruptive pseudoangiomatosis, and papular-purpuric gloves and socks syndrome: a brief review and arguments for diagnostic criteria. ( 24470919 )	Chuh A....Sciallis G.	2012
49	A challenging case: Symmetrical drug related intertriginous and flexural exanthem, fixed drug eruption, or both? ( 22082466 )	Ozkaya E....Babuna G.	2011
50	Drug-induced exanthem following dabigatran. ( 21881034 )	Whitehead H....Hummel J.	2011

Sources

Genes for Exanthem

Genes related to Exanthem (0 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CD40LG	CD40 Ligand	Protein Coding	18.49	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
2	EGFR	Epidermal Growth Factor Receptor	Protein Coding	17.59	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
3	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	17.15	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
4	NLRP3	NLR Family Pyrin Domain Containing 3	Protein Coding	16.92	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
5	CD79A	CD79a Molecule	Protein Coding	16.78	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
6	TLR9	Toll Like Receptor 9	Protein Coding	16.67	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
7	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	16.61	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
8	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	16.57	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
9	CRP	C-Reactive Protein	Protein Coding	16.52	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
10	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	16.36	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
11	TNFRSF1B	TNF Receptor Superfamily Member 1B	Protein Coding	16.21	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
12	HSPG2	Heparan Sulfate Proteoglycan 2	Protein Coding	16.1	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
13	TRIM21	Tripartite Motif Containing 21	Protein Coding	16.05	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
14	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	16.02	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
15	TNF	Tumor Necrosis Factor	Protein Coding	15.93	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
16	IL2	Interleukin 2	Protein Coding	15.78	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
17	KALRN	Kalirin RhoGEF Kinase	Protein Coding	15.75	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
18	IL6	Interleukin 6	Protein Coding	15.7	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
19	AREG	Amphiregulin	Protein Coding	6.99	DISEASES inferred ¹⁵ ¹⁵
20	SENP8	SUMO Peptidase Family Member, NEDD8 Specific	Protein Coding	6.64	DISEASES inferred ¹⁵

Sources

Variations for Exanthem

Sources

Expression for Exanthem

Search GEO for disease gene expression data for Exanthem.

Sources

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 97)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.93	AREG CD40LG EGFR ERBB2 HRAS HSPG2
2	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.87	CD40LG CD79A CRP EGFR ERBB2 HRAS
3	PEDF Induced Signaling ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Cytokine-cytokine receptor interaction ³⁷ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Mediated Glucocorticoid Regulation ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.75	CD40LG EGFR ERBB2 HRAS IL1RN IL2
4	Activation of cAMP-Dependent PKA ⁶⁴ Show member pathways Activation of PKA through GPCR ⁶⁴ cAMP Pathway ⁶⁴ PKA Signaling ⁶⁴	13.65	AREG CRP EGFR ERBB2 HRAS IL2
5	Class I MHC mediated antigen processing and presentation ⁶⁶ Show member pathways Adaptive Immune System ⁶⁶ Antigen processing- Ubiquitination and Proteasome degradation ⁶⁶	13.54	CD40LG CD79A EGFR ERBB2 HRAS KRAS
6	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.52	AREG EGFR ERBB2 HRAS IL2 IL6
7	CREB Pathway ⁶⁴ Show member pathways Activation of PKC through GPCR ⁶⁴ Intracellular Calcium Signaling ⁶⁴ IP3 Pathway ⁶⁴	13.41	AREG CD79A EGFR ERBB2 HRAS IL2
8	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.36	AREG EGFR ERBB2 HRAS IL2 IL6
9	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.31	AREG CD40LG EGFR ERBB2 HRAS IL2
10	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.28	CD40LG EGFR ERBB2 HRAS IL1RN IL2
11	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.14	AREG EGFR HRAS IL2 IL6 KRAS
12	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.08	AREG CD40LG EGFR ERBB2 HRAS IL2
13	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.07	AREG CD79A EGFR HRAS HSPG2 IL2
14	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	13.02	CD40LG CD79A EGFR HRAS KRAS TNF
15	Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Show member pathways Adipokines and Insulin Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Signaling Pathway ¹ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ IL-9 Signaling Pathways ⁶⁵ Immune response IL-4 signaling pathway ²² Immune response IL-9 signaling pathway ²²	12.98	HRAS IL2 IL6 KRAS MTOR TNF
16	Allograft rejection ¹ ³⁷ Show member pathways Antigen processing and presentation ³⁷ Asthma ³⁷ Autoimmune thyroid disease ³⁷ CTL Mediated Apoptosis ⁶⁴ Graft-versus-host disease ³⁷ Intestinal immune network for IgA production ³⁷ THC Differentiation Pathway ⁶⁴ Type I diabetes mellitus ³⁷ Viral myocarditis ³⁷	12.97	CD40LG HRAS IL2 IL6 TNF TNFRSF1B
17	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.97	EGFR ERBB2 HRAS IL6 KRAS MTOR
18	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.97	AREG EGFR ERBB2 HRAS KRAS MTOR
19	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ DR3 Signaling ⁶⁴ Fas Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.95	HRAS IL6 KRAS TNF TNFRSF1B
20	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.94	AREG EGFR ERBB2 HRAS IL2 IL6
21	IL-2 Pathway ⁶⁴ Show member pathways HMGB1 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TREM1 Pathway ⁶⁴	12.9	CD79A HRAS IL2 KRAS TLR9 TNF
22	Pathways in cancer ³⁷	12.9	EGFR ERBB2 HRAS IL2 IL6 KRAS
23	ErbB4 Pathway ⁶⁴ Show member pathways ErbB Family Pathway ⁶⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ Growth Hormone Signaling ⁶⁴ IL-4 Pathway ⁶⁴ Prolactin Signaling ⁶⁴ Thrombopoietin Pathway ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	12.87	AREG EGFR ERBB2 HRAS KRAS MTOR
24	Influenza A ³⁷ Show member pathways Herpes simplex infection ³⁷ Measles ³⁷	12.86	IL2 IL6 NLRP3 TLR9 TNF
25	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.86	EGFR ERBB2 HRAS IL6 KRAS MTOR
26	MAPK signaling pathway ¹ ³⁷	12.85	AREG EGFR ERBB2 HRAS KRAS TNF
27	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.83	EGFR ERBB2 HRAS KRAS MTOR
28	Downstream signaling events of B Cell Receptor (BCR) ⁶⁶ Show member pathways Activation of RAS in B cells ⁶⁶ Signaling by the B Cell Receptor (BCR) ⁶⁶	12.81	CD79A EGFR ERBB2 HRAS KRAS MTOR
29	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.75	CD40LG EGFR HRAS KRAS TNF TNFRSF1B
30	Regulation of IFNA signaling ⁶⁶ Show member pathways Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Interleukin-19, 20, 22, 24 ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Jak-STAT signaling pathway ³⁷	12.71	EGFR HRAS IL2 IL6 MTOR TNF
31	Kaposi's sarcoma-associated herpesvirus infection ³⁷ Show member pathways Hepatitis B ³⁷	12.65	HRAS HSPG2 IL6 KRAS MTOR TNF
32	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.64	EGFR ERBB2 HRAS IL2 IL6 KRAS
33	MicroRNAs in cancer ³⁷	12.62	EGFR ERBB2 HRAS KRAS MTOR
34	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.62	AREG CD40LG EGFR IL2 IL6 TLR9
35	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.61	AREG EGFR ERBB2 HRAS KRAS MTOR
36	TRAF Pathway ⁶⁴ Show member pathways 14-3-3 Induced Apoptosis ⁶⁴ TNF Superfamily Pathway ⁶⁴ Toll-Like Receptors Pathway ⁶⁴	12.59	CD40LG TLR9 TNF TNFRSF1B
37	NF-kappaB Signaling ⁴	12.59	CD40LG CD79A IL1RN IL2 TLR9 TNF
38	Prolactin Signaling Pathway ¹ ³⁷ Show member pathways Development Prolactin receptor signaling ²² Leptin signaling pathway ¹	12.58	ERBB2 HRAS IL1RN KRAS MTOR
39	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.53	AREG EGFR ERBB2 HRAS KRAS MTOR
40	HTLV-I infection ³⁷	12.52	HRAS IL2 IL6 KRAS TNF
41	mTOR signaling pathway (KEGG) ⁶⁵ Show member pathways mTOR signaling pathway ³⁷	12.52	EGFR ERBB2 HRAS KRAS MTOR TNF
42	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.49	EGFR ERBB2 HRAS IL2 KRAS MTOR
43	T cell receptor signaling pathway ³⁷ Show member pathways T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.46	CD40LG HRAS IL2 IL6 KRAS TNF
44	MET promotes cell motility ⁶⁶ Show member pathways Alpha 6 Beta 4 signaling pathway ¹ Laminin interactions ⁶⁶ MET activates PTK2 signaling ⁶⁶ MET activates RAP1 and RAC1 ⁶⁶ MET activates RAS signaling ⁶⁶ MET interacts with TNS proteins ⁶⁶ MET Receptor Activation ⁶⁶ MET receptor recycling ⁶⁶ Signaling by MET ⁶⁶	12.42	HRAS HSPG2 KRAS MTOR
45	Folate Metabolism ¹ Show member pathways Selenium Micronutrient Network ¹ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	12.4	CRP IL2 IL6 TNF
46	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2-ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶	12.39	EGFR ERBB2 HRAS KRAS
47	Th1 Differentiation Pathway ⁶⁵ Show member pathways IL27-mediated signaling events ¹ IL-6-type cytokine receptor ligand interactions ⁶⁶ Interleukin-6 family signaling ⁶⁶ Interleukin-6 signaling ⁶⁶ Th17 Differentiation Pathway ⁶⁵	12.34	IL2 IL6 TLR9 TNF
48	VEGF Signaling Pathway ⁶⁷ ⁶¹ Show member pathways Nanoparticle-mediated activation of receptor signaling ¹ TGF-beta Signaling ⁶⁷	12.32	AREG EGFR HRAS KRAS
49	IL-1 Family Signaling Pathways ⁶⁵ Show member pathways Immune response IL-1 signaling pathway ²² Mucin expression in CF via TLRs, EGFR signaling pathways ²²	12.32	EGFR HRAS IL1RN IL6 TNF
50	Colorectal Cancer Metastasis ⁶⁴	12.27	EGFR IL6 KRAS TLR9 TNF

Sources

GO Terms for Exanthem

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	intracellular	GO:0005622	9.86	AREG CD40LG EGFR ERBB2 IL1RN IL2
2	extracellular region	GO:0005576	9.7	CD40LG CRP EGFR HSPG2 IL1RN IL2
3	membrane raft	GO:0045121	9.55	CD79A EGFR KRAS TNF TNFRSF1B
4	extracellular space	GO:0005615	9.32	AREG CD40LG CRP EGFR HSPG2 IL1RN

Biological processes related to Exanthem according to GeneCards Suite gene sharing:

(show all 41)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.99	EGFR ERBB2 HRAS TNF
2	cytokine-mediated signaling pathway	GO:0019221	9.99	IL1RN IL2 IL6 KRAS TNF TNFRSF1B
3	cell surface receptor signaling pathway	GO:0007166	9.98	CD79A EGFR ERBB2 HRAS TNFRSF1B
4	MAPK cascade	GO:0000165	9.95	EGFR ERBB2 HRAS IL2 KRAS TNF
5	positive regulation of protein kinase B signaling	GO:0051897	9.92	EGFR ERBB2 MTOR TNF
6	cellular response to lipopolysaccharide	GO:0071222	9.9	IL6 NLRP3 TNF TNFRSF1B
7	defense response to Gram-positive bacterium	GO:0050830	9.87	CRP IL6 NLRP3 TNF
8	positive regulation of cell growth	GO:0030307	9.85	EGFR ERBB2 IL2
9	positive regulation of inflammatory response	GO:0050729	9.85	EGFR IL2 TLR9
10	positive regulation of JNK cascade	GO:0046330	9.85	HRAS TLR9 TNF
11	positive regulation of translation	GO:0045727	9.85	ERBB2 IL6 MTOR
12	positive regulation of MAPK cascade	GO:0043410	9.85	EGFR ERBB2 HRAS IL6 TLR9 TNFRSF1B
13	positive regulation of T cell proliferation	GO:0042102	9.84	CD40LG IL2 IL6
14	positive regulation of epithelial cell proliferation	GO:0050679	9.84	EGFR ERBB2 HRAS
15	cellular response to growth factor stimulus	GO:0071363	9.83	EGFR ERBB2 TNFRSF1B
16	epidermal growth factor receptor signaling pathway	GO:0007173	9.83	AREG EGFR HRAS KRAS
17	cellular response to amino acid stimulus	GO:0071230	9.82	EGFR MTOR TNF
18	positive regulation of interleukin-6 production	GO:0032755	9.81	IL6 TLR9 TNF
19	positive regulation of NIK/NF-kappaB signaling	GO:1901224	9.81	EGFR TLR9 TNF
20	positive regulation of smooth muscle cell proliferation	GO:0048661	9.8	EGFR IL6 MTOR TNF
21	response to glucocorticoid	GO:0051384	9.8	AREG IL1RN IL6 KRAS TNF
22	positive regulation of interferon-gamma production	GO:0032729	9.79	HRAS IL2 TNF
23	positive regulation of DNA replication	GO:0045740	9.78	AREG EGFR HRAS
24	positive regulation of gene expression	GO:0010628	9.76	CRP ERBB2 HRAS IL6 KRAS MTOR
25	ERBB2 signaling pathway	GO:0038128	9.73	EGFR ERBB2 HRAS KRAS
26	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.73	CD40LG IL6 KRAS